Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Hongjing Zang(Central South University), Shi‐Yong Sun(Emory University)

Molecular Oncology

January 31, 2020

10.1002/1878-0261.12645

Cited by 38

Related Papers

Effects of Deguelin on the Phosphatidylinositol 3-Kinase/Akt Pathway and Apoptosis in Premalignant Human Bronchial Epithelial Cells

|JNCI Journal of the National Cancer Institute|2003|257

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

|Journal of Thoracic Oncology|2020|166

The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells

|Cancer Research|2007|164

Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

|Cancer Research|2008|159

Inhibition of IκB Kinase-Nuclear Factor-κB Signaling Pathway by 3,5-Bis(2-flurobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin

|Molecular Pharmacology|2008|158